Strongbridge Biopharma plc (NASDAQ:SBBP) was the recipient of a large drop in short interest in the month of September. As of September 28th, there was short interest totalling 709,338 shares, a drop of 34.0% from the September 14th total of 1,075,149 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average trading volume of 498,809 shares, the days-to-cover ratio is currently 1.4 days.

NASDAQ:SBBP opened at $5.00 on Friday. Strongbridge Biopharma has a 52-week low of $3.85 and a 52-week high of $9.25. The company has a current ratio of 6.46, a quick ratio of 6.38 and a debt-to-equity ratio of 8.76. The stock has a market cap of $226.54 million, a PE ratio of -3.45 and a beta of 0.80.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.41. The company had revenue of $4.30 million for the quarter, compared to the consensus estimate of $4.53 million. On average, research analysts expect that Strongbridge Biopharma will post -1.8 earnings per share for the current year.

Several research analysts recently commented on SBBP shares. BidaskClub downgraded shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, June 26th. Janney Montgomery Scott initiated coverage on shares of Strongbridge Biopharma in a report on Thursday, June 28th. They set a “buy” rating on the stock. Zacks Investment Research upgraded shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. HC Wainwright set a $18.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Thursday, August 9th. Finally, Cantor Fitzgerald set a $17.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $14.75.

In other news, major shareholder Associates L.L.C. Cdk bought 70,000 shares of the company’s stock in a transaction that occurred on Monday, July 30th. The shares were purchased at an average price of $4.66 per share, for a total transaction of $326,200.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders purchased a total of 910,795 shares of company stock worth $4,430,231 in the last quarter. Insiders own 4.20% of the company’s stock.

Several institutional investors have recently modified their holdings of SBBP. Lyon Street Capital LLC boosted its position in shares of Strongbridge Biopharma by 126.3% during the 1st quarter. Lyon Street Capital LLC now owns 3,182,149 shares of the biotechnology company’s stock valued at $28,162,000 after acquiring an additional 1,776,054 shares in the last quarter. Harvest Capital Strategies LLC acquired a new stake in shares of Strongbridge Biopharma during the 1st quarter valued at about $7,301,000. Millennium Management LLC boosted its position in shares of Strongbridge Biopharma by 380.4% during the 2nd quarter. Millennium Management LLC now owns 662,419 shares of the biotechnology company’s stock valued at $3,975,000 after acquiring an additional 524,539 shares in the last quarter. BlackRock Inc. boosted its position in shares of Strongbridge Biopharma by 25.4% during the 1st quarter. BlackRock Inc. now owns 1,795,693 shares of the biotechnology company’s stock valued at $15,892,000 after acquiring an additional 363,328 shares in the last quarter. Finally, Opaleye Management Inc. boosted its position in shares of Strongbridge Biopharma by 15.1% during the 2nd quarter. Opaleye Management Inc. now owns 1,830,000 shares of the biotechnology company’s stock valued at $10,980,000 after acquiring an additional 240,000 shares in the last quarter. Institutional investors and hedge funds own 66.89% of the company’s stock.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Featured Story: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.